This list is based on the watchlists of people on Stock Events who follow 0LT7.LSE. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.
Show more...
FAQ
What is Elektrotim stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Elektrotim stocks are traded under the ticker 0LT7.LSE.
What is Elektrotim revenue for the last year?▼
Elektrotim revenue for the last year amounts to 1.05B PLN.
What is Elektrotim net income for the last year?▼
0LT7.LSE net income for the last year is 108.14M PLN.
Does Elektrotim pay dividends?▼
Yes, 0LT7.LSE dividends are paid annual. The last dividend per share was 2.5 PLN. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Elektrotim located?▼
Elektrotim operates in the Other sector.
When did Elektrotim complete a stock split?▼
Elektrotim has not had any recent stock splits.